NAMS

NewAmsterdam Pharma Company NV

Add to Watchlist

Advanced Chart

18.370

-0.900(-4.670%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

19.825

Open

19.290

VWAP

18.68

Vol

974.27K

Mkt Cap

2.06B

Low

18.265

Amount

18.20M

EV/EBITDA(TTM)

Total Shares

89.99M

1.25B

EV/OCF(TTM)

P/S(TTM)

39.46

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q1

1.54M

-32.4%

1.57M

+12.31%

Estimates Revision

The market is revising Upward the revenue expectations for NewAmsterdam Pharma Company N.V. (NAMS) for FY2025, with the revenue forecasts being adjusted by 97.66% over the past three months. During the same period, the stock price has changed by -4.62%.

Revenue Estimates for FY2025

Revise Upward

+97.66%

In Past 3 Month

Stock Price

Go Down

-4.62%

In Past 3 Month

9 Analyst Rating

134.08% Upside

Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 43.00 USD with a low forecast of 37.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

134.08% Upside

Current: 18.370

Low

37.00

Averages

43.00

High

52.00

134.08% Upside

Current: 18.370

Low

37.00

Averages

43.00

High

52.00

Needham

Serge Belanger

Strong Buy

Maintains

$42 → $40

2025-05-08

New

Reason

Needham

Serge Belanger

Price Target

$42 → $40

2025-05-08

New

Maintains

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

$42

2025-04-08

Reason

Needham

Serge Belanger

Price Target

$42

2025-04-08

Reiterates

Strong Buy

Reason

Scotiabank

George Farmer

Buy

Maintains

$47 → $52

2025-02-27

Reason

Scotiabank

George Farmer

Price Target

$47 → $52

2025-02-27

Maintains

Buy

Reason

Needham

Serge Belanger

Strong Buy

Maintains

$46 → $42

2025-02-27

Reason

Needham

Serge Belanger

Price Target

$46 → $42

2025-02-27

Maintains

Strong Buy

Reason

RBC Capital

Brian Abrahams

Buy

Reiterates

$40

2025-01-28

Reason

RBC Capital

Brian Abrahams

Price Target

$40

2025-01-28

Reiterates

Buy

Reason

RBC Capital

Leonid Timashev

Buy

Reiterates

$40

2025-01-24

Reason

RBC Capital

Leonid Timashev

Price Target

$40

2025-01-24

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS.O) is -9.62, compared to its 5-year average forward P/E of 3.89. For a more detailed relative valuation and DCF analysis to assess NewAmsterdam Pharma Company NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

3.89

Current PE

-9.62

Overvalued PE

36.85

Undervalued PE

-29.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.60

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

11.21

Undervalued EV/EBITDA

-4.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

162.19

Current PS

128.51

Overvalued PS

383.28

Undervalued PS

-58.91

Financials

Annual

Quarterly

FY2024Q4

12.77M

Total Revenue

FY2024Q4

-43.23M

Operating Profit

FY2024Q4

-92.18M

Net Income after Tax

FY2024Q4

-0.93

EPS - Diluted

FY2024Q4

-37.48M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

-65.14%

-349.49

FCF Margin - %

FY2024Q4

YoY :

-42.53%

-721.71

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.1M

USD

3-6

Months

14.0M

USD

6-9

Months

979.9K

USD

0-12

Months

0.0

USD

Bought

0-3

109.7K

USD

Months

3-6

0.0

USD

Months

6-9

17.3K

USD

Months

0-12

167.7K

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 276.36% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.7M

Volume

6-9

Months

0.0

Volume

0-12

Months

150.8K

Volume

Bought

0-3

0.0

Volume

Months

3-6

8.3M

Volume

Months

6-9

0.0

Volume

Months

0-12

2.2M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.1M

USD

3-6

Months

14.0M

USD

6-9

Months

979.9K

USD

0-12

Months

0.0

USD

Bought

0-3

109.7K

USD

Months

3-6

0.0

USD

Months

6-9

17.3K

USD

Months

0-12

167.7K

USD

Months

NAMS News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

08:02:47

NewAmsterdam Pharma reports Q1 revenue $2.978M, consensus $1.46M

2025-05-07 (ET)

2025-05-07

07:30:40

NewAmsterdam Pharma announces additional data from BROADWAY, TANDEM studies

2025-02-26 (ET)

2025-02-26

08:05:41

NewAmsterdam reports FY24 revenue $45.56M, consensus $31.13M

News

4.0

05-08Benzinga

Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $40

9.5

05-08Newsfilter

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

9.0

05-07Newsfilter

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025